A192621
| 中文名稱(chēng) | A192621 |
|---|---|
| 中文同義詞 | 化合物 T14068;化合物 A-192621 |
| 英文名稱(chēng) | A192621 |
| 英文同義詞 | (2R,3R,4S)-4-(1,3-BENZODIOXOL-5-YL)-1-[2-[(2,6-DIETHYLPHENYL)AMINO]-2-OXOETHYL]-2-(4-PROPOXYPHENYL)PYRROLIDINE-3-CARBOXYLIC ACID;A192621;A192621,CID 5310991;3-Pyrrolidinecarboxylic acid, 4-(1,3-benzodioxol-5-yl)-1-[2-[(2,6-diethylphenyl)amino]-2-oxoethyl]-2-(4-propoxyphenyl)-, (2R,3R,4S)-;A192621 >=98 (HPLC) |
| CAS號(hào) | 195529-54-5 |
| 分子式 | C33H38N2O6 |
| 分子量 | 558.66 |
| EINECS號(hào) | |
| 相關(guān)類(lèi)別 | 制劑-拮抗劑 |
| Mol文件 | 195529-54-5.mol |
| 結(jié)構(gòu)式 |  |
A192621 性質(zhì)
| 沸點(diǎn) | 738.3±60.0 °C(Predicted) |
|---|---|
| 密度 | 1.233±0.06 g/cm3(Predicted) |
| 儲(chǔ)存條件 | -20°C |
| 溶解度 | DMSO: 2mg/mL, clear |
| 形態(tài) | 粉末 |
| 酸度系數(shù)(pKa) | 3.52±0.60(Predicted) |
| 顏色 | 白色至米色 |
| InChIKey | LQEHCKYYIXQEBM-FUKIBTTHSA-N |
| SMILES | O=C(NC1=C(CC)C=CC=C1CC)CN(C[C@H](C2=CC3=C(OCO3)C=C2)[C@H]4C(O)=O)[C@H]4C5=CC=C(OCCC)C=C5 |
|
ET B 4.5 nM (IC 50 ) |
ET B 8.8 nM (Ki) |
ET A 4280 nM (IC 50 ) |
ET A 5600 nM (Ki) |
A-192621 (1-100 μM; 48 hours; PASMCs) treatment markedly reduces the cell viability of PASMCs in a dose-dependent manner.
A-192621 (1-100 μM; 48 hours; PASMCs) treatment significantly increases the caspase-3/7 activity and cleaved caspase-3 expression in PASMCs. A-192621 induces apoptosis in a dose-dependent manner and increases the cells' susceptibility to apoptosis by Doxorubicin treatment.
Cell Viability Assay
| Cell Line: | Pulmonary arterial smooth muscle cells (PASMCs) with Doxorubicin |
| Concentration: | 1 μM, 10 μM, 50 μM, 100 μM |
| Incubation Time: | 72 hours |
| Result: | The viability of PASMCs was significantly decreased in a dose-dependent manner. |
Western Blot Analysis
| Cell Line: | Pulmonary arterial smooth muscle cells (PASMCs) with Doxorubicin |
| Concentration: | 1 μM, 10 μM, 100 μM |
| Incubation Time: | 72 hours |
| Result: | The caspase-3/7 activity in PASMCs was significantly increased in a dose-dependent manner. |
A-192621 (30-100 mg/kg; oral administration; daily; for 3 days; male Sprague-Dawley rats) treatment inhibits both dilatory and pressor responses induced by S6c mediated by ET B with an ED 50 value of 30 mg/kg, and failed to inhibit the ET-1-induced pressor response mediated by ET A . A-192621 alone causes elevation of arterial blood pressure and an elevation in the plasma ET-1 level in the conscious normotensive rat.
| Animal Model: | Male Sprague-Dawley rats (250-350 g) |
| Dosage: | 30 mg/kg 100 mg/kg |
| Administration: | Oral administration; daily; for 3 days |
| Result: | Inhibited both dilatory and pressor responses induced by S6c mediated by ET B with an ED 50 value of 30 mg/kg. |
安全信息
| WGK Germany | WGK 3 |
|---|---|
| 存儲(chǔ)類(lèi)別 | 11 - 可燃固體 |
| 更新日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱(chēng) | CAS號(hào) | 包裝 | 價(jià)格 |
|---|---|---|---|---|---|
| 2026/06/05 | HY-120295 | A192621 A-192621 | 195529-54-5 | 1 mg | 1850元 |
| 2026/06/05 | HY-120295 | A192621 A-192621 | 195529-54-5 | 5mg | 4680元 |